James C. Mullen
James C. Mullen is our President and Chief Executive Officer and has served in these positions since the merger in November 2003. Mr. Mullen joined Biogen Inc. in 1989. He was named Chief Executive Officer in 2000 and Chairman in 2002. Prior to being named CEO and Chairman, he held the positions of President and Chief Operating Officer (1999-2000); Vice President, International (1996-1999); Vice President, Operations (1992-1996); and Director, Facilities and Engineering (1989-1992). Mr. Mullen is a member of the Board of Directors of PerkinElmer Inc. and the Biomedical Science Careers Program Inc. He holds a B.S. in Chemical Engineering from Rensselaer Polytechnic Institute and an M.B.A. from Villanova University.
Cecil Pickett, Ph.D.
Cecil Pickett, Ph.D., is our President, Research and Development, and has served in that position since September 2006. Prior to joining Biogen Idec, Dr. Pickett held several senior R&D positions, most recently as a Corporate Senior Vice President of Schering Plough Corp. & President of Schering-Plough Research Institute. In that capacity, Dr. Pickett helped bring several large and small molecule candidates into the Schering-Plough clinical development pipeline. Prior to joining Schering-Plough, he held several senior R&D positions at Merck & Co. Dr. Pickett received his B.Sc. in biology from California State University at Hayward and his Ph.D. in cell biology from University of California at Los Angeles.
Susan H. Alexander
Susan H. Alexander is our Executive Vice President, General Counsel and Corporate Secretary and has served in these positions since January 2006. Prior to that, Ms. Alexander had served as the Senior Vice President, General Counsel and Corporate Secretary of PAREXEL International Corp. since September 2003. From June 2001 to September 2003, Ms. Alexander served as General Counsel of IONA Technologies. From January 1995 to May 2001, Ms. Alexander served as Counsel at Cabot Corp. Prior to that, Ms. Alexander was a partner of the law firms of Hinckley, Allen & Snyder and Fine & Ambrogne.
Paul J. Clancy
Paul J. Clancy is our Executive Vice President and Chief Financial Officer and has served in these positions since August 2007. Mr. Clancy has also served as Senior Vice President of Finance and Vice President of Business Planning at Biogen Idec. Prior to the merger, Mr. Clancy had served as Vice President of Portfolio Management at Biogen Inc. since 2003. He joined the company in 2001 as Vice President, US Marketing. Before joining Biogen, Mr. Clancy spent 13 years at PepsiCo, serving in a range of financial and general management positions including most recently Vice President and General Manager of their Great West Business Unit.
John M. Dunn
John M. Dunn is our Executive Vice President, New Ventures and has served in that position since the merger in November 2003. Mr. Dunn was our Senior Vice President, Legal and Compliance, and General Counsel from January 2002 to November 2003. Prior to that, he was a partner at the law firm of Pillsbury Winthrop LLP, specializing in corporate and business representation of public and private companies.
Robert A. Hamm
Robert A. Hamm is our Chief Operating Officer and has served in that position since March 2009. Prior to that, Mr. Hamm had served as our Executive Vice President, Pharmaceutical Operations & Technology since October 2007. He served as Senior Vice President, Neurology Strategic Business Unit beginning from 2004 to 2007. Since joining the company in 1994, he has served in a variety of positions of increasing responsibility, including Senior Vice President, Europe, Africa, Canada and Middle East; Vice President, Sales and Marketing; Vice President, Manufacturing & Engineering; and Director, Northern Europe and Distributors Markets. From 1987 to 1994, he held a variety of management positions at Syntex Laboratories Corp. He is a member of the board of directors Inhibitex, Inc. and Progenitor Cell Therapy, LLC.
Michael Lytton
Michael Lytton is our Executive Vice President, Corporate and Business Development, and has served in that position since February 2009. From 2001 to 2009, he was a General Partner at Oxford Bioscience Partners, a venture capital firm. From 1993 to 2000, he was Partner, Chairman of the Technology Group and a member of the Executive Committee of the law firm Edwards, Angell, Palmer & Dodge LLP. From 1984 to 1993, Mr. Lytton was a Junior Partner and Co-Chairman of the Biotechnology Practice of the law firm Wilmer Hale.
Michael F. MacLean
Michael F. MacLean is our Senior Vice President, Chief Accounting Officer and Controller and has served in that position since December 2006. Mr. MacLean joined Biogen Idec in October 2006 as Senior Vice President. Prior to that, Mr. MacLean was a managing director of Huron Consulting, where he provided support regarding financial reporting to management and boards of directors of Fortune 500 companies. From June 2002 to October 2005, Mr. MacLean was a partner at KPMG, and from September 1999 to May 2002, he was a partner of Arthur Andersen LLP.
Craig Eric Schneier, Ph.D.
Craig Eric Schneier, Ph.D. is our Executive Vice President, Human Resources, Public Affairs & Corporate Communications and has served in that position since the merger in November 2003. Dr. Schneier was previously Executive Vice President, Human Resources of Biogen Inc., a position he held since January 2003. He joined Biogen in 2001 as Senior Vice President, Strategic Organization Design and Effectiveness, after having served as an external consultant to the company for eight years. Prior to that, Dr. Schneier was president of his own management consulting firm in Princeton, NJ, where he provided consulting services to more than 70 of the Fortune 100 companies, as well as several of the largest European and Asian firms. Dr. Schneier held a tenured professorship at the University of Maryland’s Smith School of Business and has held teaching positions at the business schools of the University of Michigan and Columbia University as well as at the Tuck School of Business, Dartmouth College.
